Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced blood disorders.

D A Danielson, S W Douglas, P Herzog

    JAMA
    |December 21, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Technical Report: Triple-Colour Staining Flow Cytometry for Co-Distribution of Thrombospondin Receptor (CD36), Ribonucleic Acid (RNA) and Fetal Haemoglobin (HbF) in Sickle Red Blood Cells.

    Hematology (Amsterdam, Netherlands)·2016
    Same author

    Raised haematocrit concentration and the risk of death and vascular complications after major surgery.

    The British journal of surgery·2013
    Same author

    Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

    Annals of hematology·2012
    Same author

    Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.

    Medicinal chemistry (Shariqah (United Arab Emirates))·2011
    Same author

    Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms.

    American journal of hematology·2010
    Same author

    Rapid flow cytometric quantitation of reticulated platelets in whole blood.

    Platelets·2010
    Same journal

    Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

    JAMA·2026
    Same journal

    Surgical and Endoscopic Therapies for GERD.

    JAMA·2026
    Same journal

    The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

    JAMA·2026
    Same journal

    "Suturing": Love, Death, and Perfection's Limits.

    JAMA·2026
    Same journal

    What Is Low Back Pain?

    JAMA·2026
    Same journal

    From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

    JAMA·2026
    See all related articles

    Drug-induced blood disorders are rare, with hospitalization rates around one per 100,000 person-years. Quinidine/quinine and sulfa drugs were most frequently implicated in these rare events.

    Area of Science:

    • Hematology
    • Pharmacology
    • Epidemiology

    Background:

    • Drug-induced blood disorders, including pancytopenia, hemolytic anemia, thrombocytopenia, and granulocytopenia, pose a significant clinical challenge.
    • Understanding the incidence and causative agents of these adverse events is crucial for patient safety and clinical practice.

    Purpose of the Study:

    • To investigate the incidence of drug-induced blood disorders.
    • To identify specific drugs associated with these hematological conditions.

    Main Methods:

    • A case-history study was conducted.
    • Data were collected over a ten-year period (1972-1981) from a large health maintenance organization.
    • Hospitalization records were analyzed for drug-induced blood disorders, excluding those caused by antitumor agents.

    Related Experiment Videos

    Main Results:

    • Twenty-six hospitalizations for drug-induced blood disorders were identified.
    • The overall incidence rate was approximately one per 100,000 person-years.
    • Quinidine/quinine and sulfa-containing drugs were the most frequently implicated agents, each associated with multiple cases.

    Conclusions:

    • Drug-induced blood disorders requiring hospitalization are rare events.
    • Specific medications, notably quinidine/quinine and sulfa drugs, are key culprits.
    • Continued pharmacovigilance is essential for identifying and mitigating risks associated with drug-induced hematotoxicity.